[go: up one dir, main page]

MX2012010148A - Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion. - Google Patents

Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion.

Info

Publication number
MX2012010148A
MX2012010148A MX2012010148A MX2012010148A MX2012010148A MX 2012010148 A MX2012010148 A MX 2012010148A MX 2012010148 A MX2012010148 A MX 2012010148A MX 2012010148 A MX2012010148 A MX 2012010148A MX 2012010148 A MX2012010148 A MX 2012010148A
Authority
MX
Mexico
Prior art keywords
denaturing
soluble recombinant
recombinant interferon
interferon protein
producing soluble
Prior art date
Application number
MX2012010148A
Other languages
English (en)
Inventor
Jeffrey Allen
Ping-Hua Feng
Anant Patkar
Keith L Haney
Lawrence Chew
Lei Lei Phokham Sengchanthalangsy
Original Assignee
Pfenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfenex Inc filed Critical Pfenex Inc
Publication of MX2012010148A publication Critical patent/MX2012010148A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se relaciona con el campo del rendimiento de proteína recombinante en anfitriones bacterianos. Adicionalmente se relaciona con la extracción de la proteína recombinante activa, soluble de una fracción insoluble sin el uso de desnaturalización y sin la necesidad de una etapa de replegado. En particular, la presente invención se relaciona con un proceso de producción para obtener altos niveles de la proteína recombinante de interferón Tipo 1 soluble de un hospedero bacteriano.
MX2012010148A 2010-03-04 2011-03-02 Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion. MX2012010148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31067110P 2010-03-04 2010-03-04
PCT/US2011/026921 WO2011109556A2 (en) 2010-03-04 2011-03-02 Method for producing soluble recombinant interferon protein without denaturing

Publications (1)

Publication Number Publication Date
MX2012010148A true MX2012010148A (es) 2013-01-22

Family

ID=44531690

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010148A MX2012010148A (es) 2010-03-04 2011-03-02 Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion.

Country Status (16)

Country Link
US (2) US9187543B2 (es)
EP (1) EP2542574B1 (es)
JP (1) JP5840148B2 (es)
KR (1) KR101857825B1 (es)
CN (1) CN102906108B (es)
AU (1) AU2011223627B2 (es)
BR (1) BR112012022292A2 (es)
CA (1) CA2791361C (es)
CL (1) CL2012002378A1 (es)
CO (1) CO6592086A2 (es)
ES (1) ES2639398T3 (es)
MX (1) MX2012010148A (es)
NZ (1) NZ602255A (es)
PE (1) PE20130557A1 (es)
RU (1) RU2573909C2 (es)
WO (1) WO2011109556A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012010148A (es) 2010-03-04 2013-01-22 Pfenex Inc Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion.
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CN104151420A (zh) * 2013-05-15 2014-11-19 复旦大学 长效干扰素及其制备方法和用途
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
CN107099569B (zh) * 2017-06-30 2021-05-07 北京生物制品研究所有限责任公司 一种规模化发酵生产重组人干扰素β1b蛋白的方法
US20240050559A1 (en) * 2020-06-09 2024-02-15 Icosavax, Inc. Method of making virus-like particle
CN116120424A (zh) * 2022-06-06 2023-05-16 江苏靶标生物医药研究所有限公司 一种干扰素α2b可溶性重组表达和分离纯化方法及其应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US5702699A (en) 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
US5643566A (en) 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4462940A (en) 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4695455A (en) 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US4695462A (en) 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
GB8517071D0 (en) 1985-07-05 1985-08-14 Hoffmann La Roche Gram-positive expression control sequence
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
JP2618618B2 (ja) 1988-03-04 1997-06-11 協和醗酵工業株式会社 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5128130A (en) 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
US5055294A (en) 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5169760A (en) 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
JPH05502463A (ja) 1990-09-28 1993-04-28 オーソ・フアーマシユーチカル・コーポレーシヨン ハイブリツド成長因子
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5240834A (en) * 1991-01-22 1993-08-31 Albert Einstein College Of Medicine Of Yeshiva University Solubilization of protein after bacterial expression using sarkosyl
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US6171824B1 (en) 1991-08-30 2001-01-09 Fred Hutchinson Cancer Research Center Hybrid cytokines
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
ITFI940106A1 (it) 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
RU2098124C1 (ru) * 1994-10-24 1997-12-10 Общество с ограниченной ответственностью "Ниготек" Способ получения интерферона
IT1285405B1 (it) 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
US5814485A (en) 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
CA2309766C (en) 1997-11-20 2008-09-30 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
WO1999058662A1 (fr) 1998-05-14 1999-11-18 Merck Patent Gmbh Proteine fusionnee
US20030167531A1 (en) 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
MXPA01008176A (es) 1999-02-18 2002-08-30 Rmf Dictagene Sa Vacuna contra el paludismo.
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
KR100358948B1 (ko) 2000-03-31 2002-10-31 한국과학기술원 인체 과립성 백혈구의 콜로니 자극인자를 분비하는 대장균
US6946548B2 (en) 2000-09-08 2005-09-20 Massachusetts Institute Of Technology G-CSF analog compositions and methods
PT1343518E (pt) 2000-11-07 2009-08-03 Novartis Vaccines & Diagnostic Composições de interferão estabilizadas
PL363501A1 (en) 2001-02-06 2004-11-29 Merck Patent Gmbh Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
RU2363707C2 (ru) 2001-02-19 2009-08-10 Мерк Патент Гмбх Искусственные белки с пониженной иммуногенностью
JP4279554B2 (ja) 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
KR100961859B1 (ko) 2001-07-11 2010-06-09 맥시겐 홀딩스 엘티디 지-씨에스에프 접합체
AU2002330091A1 (en) * 2001-09-10 2003-03-24 Emd Biosciences, Inc. Method for recovering and analyzing a cellular component of cultured cells without having to harvest the cells first
US20040247562A1 (en) 2001-09-28 2004-12-09 Sang Yup Lee Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3
DK2279755T3 (da) 2001-10-10 2014-05-26 Ratiopharm Gmbh Remodellering og glycokonjugering af fibroblastvækstfaktor (FGF)
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
AU2003267827A1 (en) 2002-08-31 2004-03-19 Cj Corp. Glycosylated human granulocyte colony-stimulating factor (g-csf) isoform
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US8399217B2 (en) 2003-03-14 2013-03-19 Brookhaven Science Associates, Llc High density growth of T7 expression strains with auto-induction option
WO2005052151A1 (en) 2003-11-19 2005-06-09 Dow Global Technologies Inc. Improved protein expression systems
WO2005089093A2 (en) 2003-11-21 2005-09-29 Dow Global Technologies Inc. Improved expression systems with sec-system secretion
KR100524872B1 (ko) * 2003-12-04 2005-11-01 씨제이 주식회사 인터페론 베타의 정제방법
PL1709170T3 (pl) 2004-01-16 2018-06-29 Pfenex Inc. Ekspresja białek ssaczych w Pseudomonas fluorescens
BRPI0513826A2 (pt) 2004-07-26 2010-06-22 Dow Global Technologies Inc processo para expressão de proteìna melhorada através de engenharia de cepa
WO2006067804A2 (en) 2004-12-20 2006-06-29 Cadila Healthcare Limited Process for preparing high levels of interferon beta
EP1828241A1 (en) 2004-12-23 2007-09-05 Laboratoires Serono S.A. G-csf polypeptides and uses thereof
GB0605684D0 (en) 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
MX2008015213A (es) 2006-05-30 2008-12-09 Dow Global Technologies Inc Metodo de optimizacion de codon.
EP1939212A1 (en) * 2006-12-20 2008-07-02 LEK Pharmaceuticals D.D. Organic compounds
KR101491867B1 (ko) 2007-01-31 2015-02-10 피페넥스 인크. 증가된 발현을 위한 박테리아 리더 서열
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008134461A2 (en) 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
FI3660032T3 (fi) 2009-06-25 2025-12-18 Amgen Inc Ei-nisäkäsperäisessä järjestelmässä ekspressoitujen proteiinien sieppauspuhdistusmenetelmiä
MX2012010148A (es) 2010-03-04 2013-01-22 Pfenex Inc Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion.
PL2552949T3 (pl) 2010-04-01 2017-01-31 Pfenex Inc. Sposoby wytwarzania G-CSF w komórce gospodarza Pseudomonas

Also Published As

Publication number Publication date
CN102906108A (zh) 2013-01-30
US20160032345A1 (en) 2016-02-04
EP2542574A2 (en) 2013-01-09
CL2012002378A1 (es) 2014-01-10
US9611499B2 (en) 2017-04-04
US20110217784A1 (en) 2011-09-08
CA2791361A1 (en) 2011-09-09
EP2542574A4 (en) 2014-01-29
AU2011223627B2 (en) 2015-06-18
CO6592086A2 (es) 2013-01-02
KR20130018743A (ko) 2013-02-25
AU2011223627A1 (en) 2012-09-27
ES2639398T3 (es) 2017-10-26
JP5840148B2 (ja) 2016-01-06
EP2542574B1 (en) 2017-08-09
RU2012141653A (ru) 2014-04-10
BR112012022292A2 (pt) 2017-01-10
CA2791361C (en) 2018-06-12
NZ602255A (en) 2014-04-30
JP2013524775A (ja) 2013-06-20
RU2573909C2 (ru) 2016-01-27
CN102906108B (zh) 2016-01-20
WO2011109556A2 (en) 2011-09-09
PE20130557A1 (es) 2013-05-19
WO2011109556A3 (en) 2012-01-12
KR101857825B1 (ko) 2018-05-14
US9187543B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
EP2542574A4 (en) METHOD FOR PRODUCING A SOLUBLE AND RECOMBINANT INTERFERON PROTEIN WITHOUT DENATURING
CY1122800T1 (el) Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων
WO2019126634A3 (en) Targeted integration of nucleic acids
HK1206761A1 (en) Nutritive fragments, proteins and methods
MX2014001383A (es) Colageno 7 y metodos relacionados.
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
WO2014028453A3 (en) Natural killer cells and uses thereof
MX348071B (es) Variantes de fc.
EP2470670A4 (en) COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
MX2015016380A (es) Produccion de productos de la proteina de leguminosa con astringencia reducida.
CY1118856T1 (el) Εμβολιο pcsk9
MX2017000014A (es) Metodo para producir acido graso de cadena media con el uso de beta-cetoacil-proteina portadora de acilo (acp) sintasa.
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
MY180953A (en) Acyl-acp thioesterase
NZ590143A (en) Anti-inflammatory proteins and methods of preparation and use thereof
NZ742660A (en) Variants of chymosin with improved milk-clotting properties
IN2015DN03206A (es)
WO2014122161A3 (en) Use of polypeptides having protease activity in animal feed
PH12012502188B1 (en) Thioesterase and method for producing fatty acid or lipid using same
WO2018132821A3 (en) Elastomeric proteins
NZ596501A (en) Casb7439 constructs
MY182519A (en) Method for producing lipid using acyl-acp thioesterase
WO2011123570A3 (en) Methods for g-csf production in a pseudomonas host cell
WO2015143512A3 (en) Enhancement of recombinant protein expression with copper